Beigene has started using its flagship biopharmaceutical production base and clinical research center in the USA to continue driving global business expansion and bringing innovative drugs to more patients worldwide.

The new flagship facility located in New Jersey, USA, with a total investment of 0.8 billion US dollars, has advanced production capacity and clinical development capabilities for new anti-cancer drugs, which will support the company's global business growth and expansion. Hopewell, New Jersey, USA, July 23, 2024 / PRNewswire / - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global innovative oncology company. Today, it announced the official opening of its new flagship base in Princeton West Innovation Park, Hopewell, New Jersey, USA. The base has been built with world-class technology.

PR NewswireJul 23 08:26 ET

Express News | BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment

BenzingaJul 23 07:09 ET

Express News | Beigene: Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility

ReutersJul 23 07:01 ET

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

BusinesswireJul 23 07:00 ET

Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus

Seeking AlphaJul 19 14:40 ET

BeiGene Appoints CFO

MT NewswiresJul 18 09:07 ET